Sunshine Biopharma, Inc.
SBFM
$1.25
$0.032.46%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -2.16M | -1.20M | -494.30K | -1.28M | -1.25M |
| Total Depreciation and Amortization | 65.40K | 64.60K | 50.90K | 42.60K | 42.40K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 0.00 | 0.00 | 0.00 | 12.00K | 400.00 |
| Change in Net Operating Assets | -1.31M | -227.80K | -4.13M | -1.96M | -1.48M |
| Cash from Operations | -3.41M | -1.36M | -4.58M | -3.19M | -2.69M |
| Capital Expenditure | -102.60K | -517.00K | -974.50K | -62.90K | 382.40K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -428.90K | -61.40K | 432.30K | -605.80K | -651.60K |
| Cash from Investing | -531.50K | -578.40K | -542.20K | -668.70K | -269.20K |
| Total Debt Issued | 347.90K | -- | -- | -- | -- |
| Total Debt Repaid | 87.90K | -29.70K | -28.60K | -29.60K | -32.90K |
| Issuance of Common Stock | 1.62M | 1.90M | 0.00 | 8.57M | 2.30K |
| Repurchase of Common Stock | 0.00 | 0.00 | 0.00 | -3.14M | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2.05M | 1.87M | -28.60K | 5.40M | -30.50K |
| Foreign Exchange rate Adjustments | -635.30K | 772.30K | -777.90K | -402.40K | 435.60K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.52M | 698.90K | -5.93M | 1.14M | -2.55M |